Correspondence 0001213900-25-069660 from MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252) (MYNZ)
MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252)
Date: July 31, 2025 · CIK: 0001874252 · Accession: 0001213900-25-069660
AI Filing Summary & Sentiment
Reasoning
Letter
Mainz Biomed N.V.
Robert Koch Strasse
55129 Mainz
Germany
July 31, 2025
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Mainz Biomed N.V.
Registration Statement on Form F-1
File No. 333- 289095
Ladies and Gentlemen:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 8:00 am Eastern Time on Monday August 4, 2025, or as soon thereafter as practicable.
The Company understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
The undersigned respectfully requests that it be notified of the effectiveness of the above-referenced Registration Statement by telephone call to our counsel, Ortoli Rosenstadt LLP, by calling Tim Dockery at (212) 829-8946.
Very truly yours,
MAINZ BIOMED N.V.
Show Raw Text
CORRESP 1 filename1.htm Mainz Biomed N.V. Robert Koch Strasse 50 55129 Mainz Germany July 31, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Mainz Biomed N.V. Registration Statement on Form F-1 File No. 333- 289095 Ladies and Gentlemen: The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 8:00 am Eastern Time on Monday August 4, 2025, or as soon thereafter as practicable. The Company understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement. The undersigned respectfully requests that it be notified of the effectiveness of the above-referenced Registration Statement by telephone call to our counsel, Ortoli Rosenstadt LLP, by calling Tim Dockery at (212) 829-8946. Very truly yours, MAINZ BIOMED N.V. By: /s/ William J. Caragol Name: William J. Caragol Title: Chief Financial Officer